695 related articles for article (PubMed ID: 15294142)
1. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
Deane R; Wu Z; Sagare A; Davis J; Du Yan S; Hamm K; Xu F; Parisi M; LaRue B; Hu HW; Spijkers P; Guo H; Song X; Lenting PJ; Van Nostrand WE; Zlokovic BV
Neuron; 2004 Aug; 43(3):333-44. PubMed ID: 15294142
[TBL] [Abstract][Full Text] [Related]
2. LRP in amyloid-beta production and metabolism.
Bu G; Cam J; Zerbinatti C
Ann N Y Acad Sci; 2006 Nov; 1086():35-53. PubMed ID: 17185504
[TBL] [Abstract][Full Text] [Related]
3. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes.
Ito S; Ohtsuki S; Kamiie J; Nezu Y; Terasaki T
J Neurochem; 2007 Dec; 103(6):2482-90. PubMed ID: 17908238
[TBL] [Abstract][Full Text] [Related]
4. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway.
Ito S; Ueno T; Ohtsuki S; Terasaki T
J Neurochem; 2010 Jun; 113(5):1356-63. PubMed ID: 20367755
[TBL] [Abstract][Full Text] [Related]
5. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor.
Elder GA; Cho JY; English DF; Franciosi S; Schmeidler J; Sosa MA; Gasperi RD; Fisher EA; Mathews PM; Haroutunian V; Buxbaum JD
J Neurochem; 2007 Aug; 102(4):1220-31. PubMed ID: 17472705
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
8. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
[TBL] [Abstract][Full Text] [Related]
9. Localization of the low-density lipoprotein receptor-related protein regions involved in binding to the A2 domain of coagulation factor VIII.
Sarafanov AG; Makogonenko EM; Andersen OM; Mikhailenko IA; Ananyeva NM; Khrenov AV; Shima M; Strickland DK; Saenko EL
Thromb Haemost; 2007 Dec; 98(6):1170-81. PubMed ID: 18064310
[TBL] [Abstract][Full Text] [Related]
10. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes.
Tamaki C; Ohtsuki S; Terasaki T
Mol Pharmacol; 2007 Oct; 72(4):850-5. PubMed ID: 17609417
[TBL] [Abstract][Full Text] [Related]
11. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
[TBL] [Abstract][Full Text] [Related]
12. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.
Pflanzner T; Janko MC; André-Dohmen B; Reuss S; Weggen S; Roebroek AJ; Kuhlmann CR; Pietrzik CU
Neurobiol Aging; 2011 Dec; 32(12):2323.e1-11. PubMed ID: 20630619
[TBL] [Abstract][Full Text] [Related]
13. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
Deane R; Du Yan S; Submamaryan RK; LaRue B; Jovanovic S; Hogg E; Welch D; Manness L; Lin C; Yu J; Zhu H; Ghiso J; Frangione B; Stern A; Schmidt AM; Armstrong DL; Arnold B; Liliensiek B; Nawroth P; Hofman F; Kindy M; Stern D; Zlokovic B
Nat Med; 2003 Jul; 9(7):907-13. PubMed ID: 12808450
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice.
Hong H; Liu LP; Liao JM; Wang TS; Ye FY; Wu J; Wang YY; Wang Y; Li YQ; Long Y; Xia YZ
Neuropharmacology; 2009; 56(6-7):1054-9. PubMed ID: 19285094
[TBL] [Abstract][Full Text] [Related]
15. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.
Carro E; Trejo JL; Gerber A; Loetscher H; Torrado J; Metzger F; Torres-Aleman I
Neurobiol Aging; 2006 Sep; 27(9):1250-7. PubMed ID: 16183170
[TBL] [Abstract][Full Text] [Related]
17. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis.
Herzig MC; Winkler DT; Burgermeister P; Pfeifer M; Kohler E; Schmidt SD; Danner S; Abramowski D; Stürchler-Pierrat C; Bürki K; van Duinen SG; Maat-Schieman ML; Staufenbiel M; Mathews PM; Jucker M
Nat Neurosci; 2004 Sep; 7(9):954-60. PubMed ID: 15311281
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
19. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Gervais F; Paquette J; Morissette C; Krzywkowski P; Yu M; Azzi M; Lacombe D; Kong X; Aman A; Laurin J; Szarek WA; Tremblay P
Neurobiol Aging; 2007 Apr; 28(4):537-47. PubMed ID: 16675063
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
